Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565717 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1564591 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1564597 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1565719 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL477665 | 0.84 | PPM1D (0.36) | PPM1D | |
| SCHEMBL477666 | 0.84 | PPM1D (0.36) | PPM1D | |
| SCHEMBL21826775 | 0.84 | PPM1D (0.36) | PPM1D | |
| SCHEMBL13581959 | 0.79 | PPM1D (0.37) | PPM1D | |
| SCHEMBL13581958 | 0.79 | PPM1D (0.37) | PPM1D | |
| SCHEMBL20696426 | 0.77 | PPM1D (0.41) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785438-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2308877-B1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-19 | — | — | US | disclosed |
| US-8436012-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2308877-A1 | IMIDAZOPYRIDIN-2-ON DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MTOR, MAPKAP1, RICTOR | PPM1D 484/4885 |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MTOR, MAPKAP1, RICTOR | PPM1D 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.